
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Habiba Atta is a content associate at The American Journal of Managed Care®.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated questionnaire.

Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.

Nearly 90% of patients in the MINT trial tapered prednisone to 5 mg/day or less, with no significant safety concerns seen to date.

IL-23 inhibitors linked to lower psoriatic arthritis risk than JAK inhibitors, and IL-17 inhibitors showed higher risk.

Inebilizumab cut MG exacerbations and rescue therapy use in MINT, and a post hoc analysis found similar responses regardless of disease duration.

Most patients with hepatitis B have not been tested for HDV, but monthly treatment and reflex testing could help close the gap.

In the phase 3 ECLIPSE 1 trial, 44% on elebsiran plus tobevibart met the primary end point, with no treatment stops due to serious adverse events.

From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.

New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.

Experts from AASLD’s The Liver Meeting 2026 share the research they expect to most shape liver care, from new biomarkers to emerging MASH drugs.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

One-year open-label MINT data show sustained MG-ADL and QMG score gains with inebilizumab, including in patients who switched from placebo.

Diabetes and functional dependence predicted 3-year graft loss after MASH liver transplant, while machine learning showed limited predictive power.

Gut-derived bile acids disrupt liver metabolism through LRH-1 before visible damage, pointing to new early biomarkers for fatty liver disease.

In nonobese patients in the ESSENCE trial, semaglutide improved metabolic dysfunction even with modest weight loss of 2% to 5%.

SMART-MASH found about a third more patients with cirrhosis than Agile 4 while using costly fibrosis tests in only some patients.

Started at advanced fibrosis or cirrhosis, pegozafermin lowered liver collagen below baseline and prevented liver cancer in a MASH mouse model.

Parvez Mantry, MD, shares real-world resmetirom data from AASLD 2026, including GLP-1 combination use and biopsy-sparing monitoring.

No systemic scalp psoriasis therapy raised serious adverse event risk in a network meta-analysis; only apremilast increased discontinuation.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

People with multiple sclerosis make up most of a survey linking variable-friction footwear to fewer self-reported falls.

Nathan Estrada, DPT, explains which patients, including those with multiple sclerosis, may benefit from footwear that adapts to gait.

Patients with Sjögren disease have 5-fold higher odds of depression, yet screening tools remain unvalidated, a new review finds.

Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.

Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.

Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.

Bipolar disorder can take 5 to 10 years to diagnose, and missing it can harm patients’ jobs, relationships, finances, and health.

Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

August 23rd 2026